The U.S. bioindustrial manufacturing sector faces a scale-up bottleneck due to limited pilot- and demonstration-scale infrastructure, often forcing companies to go abroad and risk losing domestic R&D and intellectual property. “Pilot facilities are critical for de-risking and scaling biotechnological processes—they play a vital role in bringing innovations to market. Right now, the U.S. lacks this kind of infrastructure,” Doug Cameron, PhD, an adviser to First Bight advisor, which founded BioWell.
The facility includes 13,000 liters of fermentation capacity and offers CDMO services, advanced laboratory space, and bioprocessing capabilities. The facility will offer on-site education and workforce development, including hands-on lab training.